Improvements in Frailty Care as Cost Effective

By HEOR Staff Writer

January 15, 2024

Frailty care improvements

Frail patients require a robust system during hospital admission to decrease deconditioning risk and hasten discharge. In recent years, a significant effort has gone into quickly identifying these patients. Specialists evaluate them as part of a Frailty Liaison Team. This study examines the effect of these metrics on patient outcomes, as published in the Future Healthcare Journal. 

The Importance of Locating and Transferring Patients at an Early Stage

According to the findings of previous research, proposed internal transfers frequently face delays or may not take place at all. In 2017, hospitals moved three-fifths of fragile patients to appropriate wards. These delays likely influence the duration of hospital stays. This assumption is based on the specialised care frailty units provide. 

A Discussion of the Research Methodology

The Frailty Liaison Team performs the Comprehensive Geriatric Assessment (CGA) on patients classified as frail. These patients receive treatment on the Clinical Decisions Unit (CDU) or the Acute Medical Unit (AMU). This study compares the length of stay for patients transferred to a frailty ward on the assessment day with those transferred after 24 hours. 

The findings of the research study

According to the findings of the study, early transfers result in a hospital stay that is reduced by more than one day. This results in a reduction in direct costs as well as a reduction in the patient’s exposure toward harm that is associated with the hospital. According to this study frailty care improvements could lead to potential annual saving of £26,640.

The Consequences That the Study Could Have

Because of the favourable findings of the study, conversations have begun regarding the possibility of improving the local frailty route. The authors will use the data to identify potential improvements in patient care and compare different discharge procedures. 

The findings of this study emphasise the need of identifying frail individuals at an early stage and transferring them to specialised wards to receive treatment. They have the potential to greatly enhance patient outcomes while also lowering the expense of healthcare. 

 

Reference url

Recent Posts

Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Therapy: A New Hope fo...

By HEOR Staff Writer

January 8, 2026

Wondering how teclistamab daratumumab therapy could change treatment options for relapsed/refractory multiple myeloma? Johnson & Johnson recently filed a Type II variation application with the European Medicines Agency (EMA), which seeks to expand TECVAYLI® (teclistamab) combined with DARZALE...
Childhood Immunization Reforms: Aligning U.S. Schedules with Global Standards

By João L. Carapinha

January 7, 2026

Aligning U.S. Childhood Immunization Schedules with International Benchmarks Recent childhood immunization reforms by the U.S. Centers for Disease Control and Prevention (CDC) follow a presidential directive...
Novartis Drug Pricing Agreement
Novartis reached a drug pricing agreement with the US government that lowers prices for innovative medicines, while the firm will launch future drugs at comparable prices across high-income countries. Novartis also introduces direct-to-patient platforms for Mayzent, Rydapt, and Tabrecta via Trump...